Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sancai Lianmei (SCLM) is a traditional Chinese medicine formulation available as granules or particles. It contains a combination of herbal ingredients including Ginseng (Panax ginseng), Asparagus cochinchinensis, and Radix Rehmanniae. The formulation is primarily studied for its effects in metabolic diseases such as type 2 diabetes mellitus and obesity-related complications. Mechanistically, it has been shown to regulate blood glucose and lipid levels—potentially through modulation of gut microbiota composition—and to reduce oxidative stress and inflammation. Preclinical studies indicate that it may improve spermatogenic function in obese mice by reducing oxidative damage and autophagy while clinical trials are ongoing for type 2 diabetes remission[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sancai lianmei.